Serina Therapeutics Stock Working Capital
| SER Stock | 4.79 0.64 15.42% |
Serina Therapeutics fundamentals help investors to digest information that contributes to Serina Therapeutics' financial success or failures. It also enables traders to predict the movement of Serina Stock. The fundamental analysis module provides a way to measure Serina Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Serina Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 99.8 K | 94.8 K | |
| Change In Working Capital | 625 K | 656.2 K |
Serina | Working Capital |
Serina Therapeutics Company Working Capital Analysis
Serina Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Serina Therapeutics Working Capital | 110.89 K |
Most of Serina Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Serina Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Serina Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Serina Therapeutics is extremely important. It helps to project a fair market value of Serina Stock properly, considering its historical fundamentals such as Working Capital. Since Serina Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Serina Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Serina Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Serina Capital Lease Obligations
Capital Lease Obligations |
|
Based on the company's disclosures, Serina Therapeutics has a Working Capital of 110.89 K. This is 99.97% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The working capital for all United States stocks is 99.99% higher than that of the company.
Serina Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Serina Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Serina Therapeutics could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics of similar companies.Serina Therapeutics is currently under evaluation in working capital category among its peers.
Serina Fundamentals
| Return On Asset | -0.45 | ||||
| Profit Margin | (2.21) % | ||||
| Operating Margin | (75.80) % | ||||
| Current Valuation | 62.84 M | ||||
| Shares Outstanding | 8.88 M | ||||
| Shares Owned By Insiders | 58.14 % | ||||
| Shares Owned By Institutions | 2.30 % | ||||
| Number Of Shares Shorted | 27.52 K | ||||
| Price To Sales | 18.03 X | ||||
| Revenue | 142 K | ||||
| EBITDA | (9.78 M) | ||||
| Net Income | (14.8 M) | ||||
| Total Debt | 4.37 M | ||||
| Book Value Per Share | (1.86) X | ||||
| Cash Flow From Operations | (7.8 M) | ||||
| Short Ratio | 1.73 X | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 57.2 M | ||||
| Total Asset | 11.96 M | ||||
| Retained Earnings | (131.01 M) | ||||
| Working Capital | 110.89 K | ||||
| Net Asset | 11.96 M |
About Serina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Serina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Serina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Serina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.